About Us


About Us

 
 
 

Revelation Biosciences, Inc. is a clinical-stage life science company developing innovative solutions to treat acute and chronic disease. Revelation was founded in 2020 by industry veterans with a proven track record of successful drug development.

We are developing a pipeline of potential high-value products based on Gemini. Gemini is our proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), an established TLR4 agonist that can stimulate the human body’s innate immune response to prevent and treat disease.

We have multiple ongoing programs to evaluate Gemini, including as a treatment for acute kidney injury (GEM-AKI), a treatment for chronic kidney disease (GEM-CKD), prevention of post-surgical infection (GEMINI-PSI), and a treatment to reduce hyperinflammation and infection associated with severe burn.

 
 

Core Values and Operating Principles


 
 
fun_583329838.jpg

Core Values

Compassion for people suffering; the patient always comes first

Truth and Transparency in all of our words and actions

Flexibility and Adaptability

Resilience

Trust and Respect in all of our interactions

Humility

values_768316024.jpg

Operating Principles

Inspire each other to be the best; improve your teammates, never stop learning

Challenge ourselves to think outside of the box

Data always trumps assumptions

Admit our mistakes and learn from them

Work with a sense of urgency, but also with excellence

Noodle on it . . .

Teamwork

Remember to take a hot minute

Have fun!

 
 

 Board of Directors

 
 

James Rolke – Chairman, Director and Chief Executive Officer Mr. Rolke cofounded and has been the Chief Executive Officer and a director of Revelation since its inception in May 2020 and became Chairman in May 2025, after the departure of Dr. George Tidmarsh. Mr. Rolke has over 30 years of experience in the biotechnology industry, spanning all areas and phases of drug development. Prior to joining the Company, beginning in 2012, Mr. Rolke was employed at La Jolla in various leadership roles overseeing Research and Development and serving as Chief Scientific Officer from 2017 to 2020. While at La Jolla, Mr. Rolke oversaw the development of multiple technologies including six INDs and two marketing approvals: Giapreza for the treatment of distributive shock (US FDA and EMEA) and artesunate for the treatment of severe malaria. Prior to La Jolla, from July 2009 to January 2012 Mr. Rolke was Chief Technology Officer at Pluromed, Inc. (acquired by Sanofi) and played a key role in the approvals of two medical devices via the 510(k) and premarket approval application approval pathways. Prior to Pluromed, Mr. Rolke held several key positions at biotechnology companies, including Director of Operations at Prospect Therapeutics, Inc., Associate Director of Pharmaceutical Development at Mersana Therapeutics, Inc., Manager of Process Development at GlycoGenesys, Inc., Principal Scientist at Surgical Sealants, Inc., Scientist at GelTex, Inc., and Associate Scientist at Alpha-Beta Technology, Inc. Mr. Rolke received his B.S. in chemistry from Keene State College. We believe that Mr. Rolke is qualified to serve as a director based on his role as our Chief Executive Officer and his extensive management experience in the biotechnology industry.

  

Jennifer Carver, B.S.N., M.B.A. - Director Ms. Carver brings over 20 years of industry experience with a focus on small biotech companies and their evolution from early development through commercialization. From 2020 to 2021, Ms. Carver has served as Chief Operating Officer at Kartos Therapeutics (Kartos). Prior to Kartos from 2014, Ms. Carver was employed at La Jolla Pharmaceutical Company in various leadership roles providing leadership through the clinical development, approval and launch of Giapreza and serving as Chief Operating Officer from 2017 to 2019. Prior to La Jolla, Ms. Carver held positions at Spectrum Pharmaceuticals and Allos Therapeutics, leading teams through the development and approval of Belionostat and Folotyn respectively. Her experience in the healthcare industry spans multiple therapeutic areas including oncology, inflammatory disease, shock, iron overload, and anti-infectives. Ms. Carver has played a critical role in negotiating key alliances, evaluation of financing opportunities, and overseeing rapid organizational growth. Ms. Carver earned her B.S.N. and M.B.A. from University of Colorado. We believe that Ms. Carver’s extensive experience working in the biotechnology industry makes her well-qualified to serve as a director.

Jess Roper C.P.A. - Director Mr. Roper has considerable financial and audit experience in the sectors of medical device, life sciences, technology, manufacturing, and financial institutions. Mr. Roper previously served as Senior Vice President and Chief Financial Officer of Dexcom, retiring in 2017 following a fulfilling and rewarding career. During his 12-year tenure, Dexcom transitioned from a pre-revenue privately held medical device company to a multi-national publicly traded entity. Mr. Roper previously held financial management positions with two other publicly traded companies and one venture funded company. He has played key roles in two initial public offerings, acquisitions/divestitures, and numerous equity and debt financings. Earlier in his career, Mr. Roper was an auditor with PricewaterhouseCoopers, and a bank and information systems examiner with the Office of the Comptroller of the Currency. He earned a Master of Science in Corporate Accountancy and a Bachelor of Science in Finance. Mr. Roper is a certified public accountant in the state of California. We believe that Mr. Roper is qualified to serve as a director based on his extensive financial and audit experience.

Lakhmir Chawla, M.D. – Director Dr. Chawla is currently the Chief Executive Officer of Exthera Medical. Previously, Dr. Chawla was the Chief Medical Officer of Silver Creek Pharma where he oversaw the Acute Ischemic Stroke development program and initiation of the ARPEGGIO neuroprotection study. Prior to that, Dr. Chawla was the Chief Medical Officer at La Jolla Pharmaceutical Company where he oversaw the development and conduct of the Phase 3 ATHOS-3 trial. Prior to joining La Jolla, Dr. Chawla was a Professor of Medicine at the George Washington University, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI) and shock. He is the author of over 160 peer-reviewed publications and a recipient of the International Vicenza Award for Critical Care Nephrology; an award that recognizes individuals who have made seminal clinical research advancements that have significantly improved the care of critically ill patients with AKI and have been adopted worldwide. He remains an active investigator in the fields of AKI biomarkers, AKI risk prediction, AKI therapeutics and chronic kidney disease caused by AKI.

 

 Management

 
 
 
 

James Rolke – Chairman, Director and Chief Executive Officer Mr. Rolke cofounded and has been the Chief Executive Officer and a director of Revelation since its inception in May 2020 and became Chairman in May 2025, after the departure of Dr. George Tidmarsh. Mr. Rolke has over 30 years of experience in the biotechnology industry, spanning all areas and phases of drug development. Prior to joining the Company, beginning in 2012, Mr. Rolke was employed at La Jolla in various leadership roles overseeing Research and Development and serving as Chief Scientific Officer from 2017 to 2020. While at La Jolla, Mr. Rolke oversaw the development of multiple technologies including six INDs and two marketing approvals: Giapreza for the treatment of distributive shock (US FDA and EMEA) and artesunate for the treatment of severe malaria. Prior to La Jolla, from July 2009 to January 2012 Mr. Rolke was Chief Technology Officer at Pluromed, Inc. (acquired by Sanofi) and played a key role in the approvals of two medical devices via the 510(k) and premarket approval application approval pathways. Prior to Pluromed, Mr. Rolke held several key positions at biotechnology companies, including Director of Operations at Prospect Therapeutics, Inc., Associate Director of Pharmaceutical Development at Mersana Therapeutics, Inc., Manager of Process Development at GlycoGenesys, Inc., Principal Scientist at Surgical Sealants, Inc., Scientist at GelTex, Inc., and Associate Scientist at Alpha-Beta Technology, Inc. Mr. Rolke received his B.S. in chemistry from Keene State College. We believe that Mr. Rolke is qualified to serve as a director based on his role as our Chief Executive Officer and his extensive management experience in the biotechnology industry.

 
 
 
 

Chester Zygmont, III – Chief Financial Officer Mr. Zygmont has been the Company’s Chief Financial Officer since inception. Mr. Zygmont brings over 20 years of experience in finance to the company with a wide range of industry applications. In 2016, Mr. Zygmont Co-Founded Jivanas, a social enterprise that owns and operates a factory in Nepal, that is focused on creating jobs for people at risk for human trafficking. Jivanas has operations in Nepal, Hong Kong, and the USA. During 2013, Mr. Zygmont Co-Founded oOxesis Biotechnology, LLC, a biologics lab that worked on developing therapies for unmet needs. From June 2012 to January 2016, Mr. Zygmont was the Senior Director of Finance, at La Jolla Pharmaceutical Company. During Mr. Zygmont’s tenure at La Jolla, he brought the company to its Nasdaq listing. Prior to La Jolla, Mr. Zygmont served as Managing Director at Z3 Capital, LLC from March 2009 to June 2012. Z3 Capital, LLC, a privately held investment firm, focused on investment acquisition and venture funding for multiple startup companies in real estate, medical device and biotechnology. Mr. Zygmont also served as Vice President at Symmetry Advisors, Inc. a private equity leveraged buyout firm. While at Symmetry, he managed all finance and accounting for its SPAC, was a key player on a $600 million buyout of a portfolio company, and subsequently led the restructuring of its manufacturing division. Mr. Zygmont earned his M.S. in Finance from Baruch College, Zicklin School of Business and his B.A. from Eastern University.

 
 
 
 

Robin Marsden – Senior Vice President, Biology Ms. Marsden has 30+ years of executive and R&D leadership directing integrated discovery, pharmacology, and translational science across a wide variety of molecules including biotherapeutics, peptides, small molecules, PEGylated therapeutics, and antibody drug conjugates (ADCs). Most recently, in her role as Senior Director of La Jolla Pharmaceutical, Robin oversaw a team of research associates and scientists, all responsible for nonclinical, bioanalytical, and biologics disciplines supporting multiple La Jolla programs. Currently, Robin is supporting all R&D related activities at Revelation Biosciences, including providing scientific rationale to support corporate and scientific strategy, authoring patents and regulatory submissions, and overseeing outsourced activities. Robin earned her Bachelor of Sciences degree in Biology from San Diego State University.

 
 
 
 
 

Carol Odle – Senior Vice President, Clinical Operations Ms. Odle has over 30 years of clinical research experience including 9 years of global clinical leadership at pharmaceutical companies, 8 years at clinical research organizations (CROs), 3 years as an executive director/partner of a clinical research site, and several years as a manager and study coordinator for multiple clinical trials. Prior to joining Revelation Biosciences, Ms. Odle was Director of Clinical Projects at La Jolla Pharmaceutical Company where she implemented and provided leadership and oversight of global clinical trials including the global trial for the FDA approved product, Giapreza.  Ms. Odle attended Skagit Valley College, Laurel School (Certified Clinical Medical Assistant) and the University of Phoenix.

 
 

 Scientific Advisory Board

 
 
 
 

Laurence Busse, MD, MBA, FCCM - Lead Principal Investigator

Critical Care Nephrologist; Medical Director for critical care at Emory Johns Creek Hospital.

 
 
 

Sean Bagshaw, MD, MSc, FRCPC

Clinician Scientist / Critical Care Nephrologist; Professor and Chair, Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, Canada.

 
 
 

Lui Forni, MD, PhD, JFICMI

Intensivist /Nephrologist; Professor of Acute Medicine and Critical Care at Royal Surrey County Hospital.

 
 
 

Stuart Goldstein, MD, FAAP, FNKF

Pediatric Nephrologist; Director for the Center for Acute Care Nephrology (CACN) at Cincinnati Children's Hospital Medical Center.

 
 
 

Javier Neyra, MD, MSCS - Principal Investigator

Critical Care Nephrologist; Professor of Medicine at UAB.

 
 
 

Peter Pickkers, MD, PhD

Internist-intensivist in Nephrology; Professor of Intensive Care Medicine at the Radboud University Medical Center Nijmegen, the Netherlands.

 
 
 

Alexander Zarbock, MD, PhD

Clinician Scientist / Critical Care Nephrologist; Director and Chair of the Department of Anesthesiology and Critical Care Medicine at the University of Münster, Germany.

 
 
 

Julia Bohannon, Ph.D.

Associate Professor in the Department of Anesthesiology and the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center.